
Overview
This guidance provides Q&A on implementing ICH Q8, Q9, and Q10 guidelines. It covers pharmaceutical development, quality risk management, design spaces, control strategies, and quality systems. G-Rex® is not referenced in this document.
What this paper found
This FDA guidance, issued in May 2026 as revision five of the ICH Q8, Q9, and Q10 Questions and Answers, clarifies how pharmaceutical development, quality risk management and the pharmaceutical quality system are applied in practice. It states that establishing a design space or using real time release testing is not necessarily expected under Quality by Design. It explains that a control strategy is required for all products, that real time release testing does not necessarily eliminate all end product testing, and that a stability monitoring protocol is required regardless of the release approach. It also says no ICH Q10 certification program exists and that firms need not buy software marketed as ICH compliant. The guidance is nonbinding.
Note: This is a nonbinding regulatory guidance with recommendations rather than legally enforceable requirements, unless specific regulatory or statutory requirements are cited.
Control strategies are expected irrespective of the development approach. — U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research
Study details
- Authors
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research
- Institution
- Center for Drug Evaluation and Research (CDER), Food and Drug Administration, U.S. Department of Health and Human Services · Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, U.S. Department of Health and Human Services
- Year
- 2026
- Cell type(s)
- Other
Explore related
Full citation
Q8, Q9, and Q10 Questions and Answers (R5): Guidance for Industry. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. 2026.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.